Mark D. Pegram

United States

Featured in: Favicon

nature.com Favicon

healio.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

ejcancer.com Favicon

cancertreatmentreviews.com

Articles

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Aug 6, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

Video content above is prompted by the following:What other potential advances are you excited about in the HR+ BC space?
Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

Aug 6, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.
Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer

Jul 29, 2024 | onclive.com | Mark D. Pegram

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

Jul 29, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram
Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

Jul 29, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

OpinionVideoJuly 29, 2024Author(s):A panel of experts discuss navigating 2L treatment strategies. Video content above is prompted by the following:What are your perceptions on efficacy and safety data on PROTACASCO 2024 #TPS1131TACTIVE-K: Phase 1b/2 study of vepdegestrant plus CDK4i PF-07220060What are your perceptions on efficacy and safety data on SERM:Lasoxifene: ASCO 2024 #TPS1127: Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclibHow do these options compare?
Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

Jul 29, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Updates in Treatment Approaches with CDK4/6 Inhibitors in HR+ Breast Cancer

Jul 8, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram
Potential with Individual Tumor Sequencing with Bespoke Testing Methodologies and ctDNA

Jul 8, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

Potential with Individual Tumor Sequencing with Bespoke Testing Methodologies and ctDNAA panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.
Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

Jun 24, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast CancerExpert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

Jun 24, 2024 | onclive.com | Kelly E McCann |Sara A. Hurvitz |Virginia Kaklamani |Mark D. Pegram

OpinionVideoJune 24, 2024Author(s):Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions. Best practices for biomarker testing in early-stage breast cancerDr. McCann to ask Dr Hurvitz:What are you typically testing for in early-stage breast cancer?